Stromal CD10 expression and relationship to the E-cadherin/β-catenin complex in breast carcinoma

Histopathology

Volumn 56, Issue 6, 2010, Pages 708-719

  Kim, Hyun Soo ^a   Kim, Gou Young ^a   Kim, Youn Wha ^a   Park, Yong Koo ^b   Song, Jeong Yoon ^a   Lim, Sung Jig ^a  

^a Kyung Hee University Hospital   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

Author keywords

Breast carcinoma; CD10; E cadherin; Stroma; catenin

Indexed keywords

BETA CATENIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; UVOMORULIN; CADHERIN; MEMBRANE METALLOENDOPEPTIDASE; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOPLASM; DISEASE ACTIVITY; DISTANT METASTASIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STROMA CELL; TUMOR VOLUME; BREAST TUMOR; CARCINOMA; FEMALE; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY;

ADULT; AGED; BETA CATENIN; BREAST NEOPLASMS; CADHERINS; CARCINOMA; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEPRILYSIN; TUMOR MARKERS, BIOLOGICAL;

EID: 77951718259     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03534.x     Document Type: Article

References (35)

1. Iwaya K, Ogawa H, Izumi M, Kuroda M, Mukai K. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virchows Arch. 2002 440 589 593.
2. Iezzi G, Piattelli A, Rubini C et al. CD10 expression in stromal cells of ameloblastoma variants. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2008 105 206 209.
3. Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod. Pathol. 2007 20 84 89.
4. Albrecht M, Gillen S, Wilhelm B, Doroszewicz J, Aumuller G. Expression, localization and activity of neutral endopeptidase in cultured cells of benign prostatic hyperplasia and prostate cancer. J. Urol. 2002 168 336 342.
5. Abdou AG. CD10 expression in tumour and stromal cells of bladder carcinoma: an association with bilharziasis. APMIS 2007 115 1206 1218.
6. Huang WB, Zhou XJ, Chen JY et al. CD10-positive stromal cells in gastric carcinoma: correlation with invasion and metastasis. Jpn. J. Clin. Oncol. 2005 35 245 250.
7. Ogawa H, Iwaya K, Izumi M et al. Expression of CD10 by stromal cells during colorectal tumor development. Hum. Pathol. 2002 33 806 811.
8. Braham H, Trimeche M, Ziadi S et al. CD10 expression by fusiform stromal cells in nasopharyngeal carcinoma correlates with tumor progression. Virchows Arch. 2006 449 220 224.
9. Gonzalez MA, Pinder SE, Wencyk PM et al. An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer. J. Pathol. 1999 187 523 529.
10. Krishnadath KK, Tilanus HW, van Blankenstein M et al. Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J. Pathol. 1997 182 331 338.
11. Gottardi CJ, Wong E, Gumbiner BM. E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J. Cell Biol. 2001 153 1049 1060.
12. Dilek FH, Topak N, Aktepe F et al. E-cadherin, beta-catenin adhesion complex and relation to matrilysin expression in pT3 rectosigmoid cancers. Pathol. Res. Pract. 2008 204 809 815.
13. Zhang G, Zhou X, Xue L et al. Accumulation of cytoplasmic beta-catenin correlates with reduced expression of E-cadherin, but not with phosphorylated Akt in esophageal squamous cell carcinoma: immunohistochemical study. Pathol. Int. 2005 55 310 317.
14. Bankfalvi A, Terpe HJ, Breukelmann D et al. Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopathology 1999 34 25 34.
15. Jeschke U, Mylonas I, Kuhn C et al. Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence. Anticancer Res. 2007 27 1969 1974.
16. Stallings-Mann M, Radisky D. Matrix metalloproteinase-induced malignancy in mammary epithelial cells. Cells Tissues Organs 2007 185 104 110.
17. McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol. Med. Today 2000 6 149 156.
18. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol. 1997 139 1861 1872.
19. Tavassoli F, Devilee P. World Health Organization classification of tumors: pathology and genetics of tumors of the breast and female genital organs.
20. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 1999 17 1474 1481.
21. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab. Invest. 2000 80 1943 1949.
22. Bilalovic N, Sandstad B, Golouh R, Nesland JM, Selak I, Torlakovic EE. CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression. Mod. Pathol. 2004 17 1251 1258.
23. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem. Biol. 1996 3 895 904.
24. Kondepudi A, Johnson A. Cytokines increase neutral endopeptidase activity in lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 1993 8 43 49.
25. Bukholm IR, Nesland JM, Bukholm G. Expression of adhesion proteins E-cadherin, alpha-catenin, beta-catenin and gamma-catenin is different in T1 and T2 breast tumours. Pathology 2006 38 403 407.
26. Yook JI, Li XY, Ota I, Fearon ER, Weiss SJ. Wnt-dependent regulation of the E-cadherin repressor snail. J. Biol. Chem. 2005 280 11740 11748.
27. Przybylo JA, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition: tumor progression at Snail's pace. Int. J. Biochem. Cell Biol. 2007 39 1082 1088.
28. Dasari V, Gallup M, Lemjabbar H, Maltseva I, McNamara N. Epithelial-mesenchymal transition in lung cancer: is tobacco the "smoking gun"? Am. J. Respir. Cell Mol. Biol. 2006 35 3 9.
29. Kinch MS, Clark GJ, Der CJ, Burridge K. Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia. J. Cell Biol. 1995 130 461 471.
30. Playford MP, Bicknell D, Bodmer WF, Macaulay VM. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc. Natl Acad. Sci. USA 2000 97 12103 12108.
31. Korinek V, Barker N, Morin PJ et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997 275 1784 1787.
32. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005 310 1504 1510.
33. Verras M, Sun Z. Beta-catenin is involved in insulin-like growth factor 1-mediated transactivation of the androgen receptor. Mol. Endocrinol. 2005 19 391 398.
34. Ohji Y, Yao T, Eguchi T et al. Evaluation of risk of liver metastasis in colorectal adenocarcinoma based on the combination of risk factors including CD10 expression: multivariate analysis of clinicopathological and immunohistochemical factors. Oncol. Rep. 2007 17 525 530.
35. Kim WH. Tissue array method for large scale clinicopathologic study. Korean J. Pathol. 2002 35 199 204.